Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.70 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.52 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2066919 | 0.89 | GPR84 (0.56) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2066613 | 0.89 | GPR84 (0.56) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL165537 | 0.89 | GPR84 (0.60) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL17646227 | 0.89 | GPR84 (0.60) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL1237975 | 0.89 | GPR84 (0.60) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL167865 | 0.89 | GPR84 (0.60) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL584656 | 0.89 | GPR84 (0.60) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL425589 | 0.89 | GPR84 (0.60) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL167222 | 0.89 | GPR84 (0.60) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL168064 | 0.89 | GPR84 (0.60) | GPR84FFAR1MAPTLCKPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3153151-B1 | SUNSCREEN HAVING REDUCED TENDENCY TO CAUSE 4-(TERT.-BUTYL)-4 - METHOXYDIBENZOYLMETHAN STAINS ON TEXTILES | BEIERSDORF AG (DE) | 2021-08-11 | — | — | EP | claimed |
| EP-3038589-B1 | EMULSIFIER-FREE, SKIN CONDITIONING, COSMETIC OR DERMATOLOGICAL PREPARATION WHICH CONTAINS PEELING ACTIVE INGREDIENTS | BEIERSDORF AG (DE) | 2019-05-01 | — | — | EP | claimed |
| US-20090142289-A1 | COMPOSITION CONTAINING A HARD WAX AND A PASTY COMPOUND, AND PROCESS FOR THE CARE OR MAKING UP OF THE EYELASHES | L'OREAL (FR) | 2009-06-04 | — | — | US | claimed |
| EP-1276455-B1 | ANHYDROUS ANTIPERSPIRANT COMPOSITION CONTAINING POLYSACCHARIDES | HENKEL AG & CO KGAA (DE) | 2008-12-24 | — | — | EP | claimed |
| EP-4366690-A1 | POLYOL ESTER MIXTURE FOR USE AS VASELINE SUBSTITUTE | BASF SE (DE) | 2024-05-15 | — | — | EP | disclosed |
| US-11964044-B2 | Phase change cosmetic composition | AMOREPACIFIC CORPORATION (KR) | 2024-04-23 | — | — | US | disclosed |
| US-20230404896-A1 | Styling Shampoo Compositions | BASF SE (DE) | 2023-12-21 | — | — | US | disclosed |
| EP-4240316-A1 | STYLING SHAMPOO COMPOSITIONS | BASF SE (DE) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023280694-A1 | POLYOL ESTER MIXTURE FOR USE AS VASELINE SUBSTITUTE | BASF SE (DE) | 2023-01-12 | — | — | WO | disclosed |
| EP-4115873-A1 | POLYOL ESTER MIXTURE FOR USE AS VASELINE SUBSTITUTE | BASF SE (DE) | 2023-01-11 | — | — | EP | disclosed |
| WO-2022096243-A1 | STYLING SHAMPOO COMPOSITIONS | BASF SE (DE) | 2022-05-12 | — | — | WO | disclosed |
| US-20210128449-A1 | PHASE CHANGE COSMETIC COMPOSITION | AMOREPACIFIC CORPORATION (KR) | 2021-05-06 | — | — | US | disclosed |
| US-20040234466-A1 | Beta-glucuronidase inhibitors for use in deodorants and antiperspirants | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2004-11-25 | — | — | US | disclosed |
| WO-2004064712-A2 | PREPARATIONS CONTAINING BEAN SPROUT EXTRACTS COMBINED WITH VITAMIN C AND/OR E AND/OR $G(A)-GLYCOSYLRUTIN | BEIERSDORF AG (DE) | 2004-08-05 | — | — | WO | disclosed |
| EP-1361856-A1 | GEL EMULSIONS IN THE FORM OF O/W EMULSIONS HAVING A HYDROCOLLOID CONTENT | Beiersdorf AG (DE) | 2003-11-19 | — | — | EP | disclosed |
| EP-1355614-A2 | LOW-LIPID COSMETIC AND DERMATOLOGICAL PREPARATIONS IN THE FORM OF O/W EMULSIONS CONTAINING FATTY ACIDS | Beiersdorf AG (DE) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002066007-A1 | GEL EMULSIONS IN THE FORM OF O/W EMULSIONS HAVING A HYDROCOLLOID CONTENT | BEIERSDORF AG (DE) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002019973-A2 | LOW-LIPID COSMETIC AND DERMATOLOGICAL PREPARATIONS IN THE FORM OF O/W EMULSIONS CONTAINING FATTY ACIDS | BEIERSDORF AG (DE) | 2002-03-14 | — | — | WO | disclosed |
| EP-0922447-A2 | Utilisation of C18-38 alkylhydroxystearoylsterates for increasing the light protection factor and/or the UV-A protection of cosmetic or dermatologic light protection agents | Beiersdorf Aktiengesellschaft (DE) | 1999-06-16 | — | — | EP | disclosed |
| US-5783176-A | CONTAINING ESTER FROM HYDROXYCARBOXYLIC ACID AND SATURATEDALCOHOL; CARING OF LIPS | BEIERSDORF AG (DE) | 1998-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040234466-A1 | Beta-glucuronidase inhibitors for use in deodorants and antiperspirants | GUSB, PON1, IDUA | GPR84 1264/4885FFAR1 1510/4885MAPT 1312/4885 |
| US-20230404896-A1 | Styling Shampoo Compositions | SGMS2, SUCLG1, PLOD3 | GPR84 2945/4885FFAR1 3338/4885MAPT 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.